User profiles for L. Marchionni
Luigi MarchionniAssociate Professor of Pathology and Laboratory Medicine, Weill Cornell Medicine Verified email at med.cornell.edu Cited by 15341 |
The transcriptional landscape of the mammalian genome
…, S McWilliam, MM Babu, M Madera, L Marchionni… - science, 2005 - science.org
This study describes comprehensive polling of transcription start and termination sites and
analysis of previously unidentified full-length complementary DNAs derived from the mouse …
analysis of previously unidentified full-length complementary DNAs derived from the mouse …
ARI: The social assistive robot and companion
…, A Di Fava, C Vivas, L Marchionni… - 2020 29th IEEE …, 2020 - ieeexplore.ieee.org
With the world population aging and the number of healthcare users with multiple chronic
diseases increasing, healthcare is becoming more costly, and as such, the need to optimise …
diseases increasing, healthcare is becoming more costly, and as such, the need to optimise …
Systematic review: gene expression profiling assays in early-stage breast cancer
Background: Three gene expression–based prognostic breast cancer tests have been licensed
for use. Purpose: To summarize evidence on the validity and utility of 3 gene expression–…
for use. Purpose: To summarize evidence on the validity and utility of 3 gene expression–…
A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro
VC Daniel, L Marchionni, JS Hierman, JT Rhodes… - Cancer research, 2009 - AACR
Traditional approaches to the preclinical investigation of cancer therapies rely on the use of
established cell lines maintained in serum-based growth media. This is particularly true of …
established cell lines maintained in serum-based growth media. This is particularly true of …
Only three driver gene mutations are required for the development of lung and colorectal cancers
… have different base pair lengths l 1 , l 2 , …, l n . It is also possible to include the effects of
differing nucleotide compositions by multiplying the various l values by a factor depending on …
differing nucleotide compositions by multiplying the various l values by a factor depending on …
Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate-and high-risk men
Background Radical prostatectomy (RP) is a primary treatment option for men with intermediate-
and high-risk prostate cancer. Although many are effectively cured with local therapy …
and high-risk prostate cancer. Although many are effectively cured with local therapy …
[HTML][HTML] Federated benchmarking of medical artificial intelligence with MedPerf
Medical artificial intelligence (AI) has tremendous potential to advance healthcare by
supporting and contributing to the evidence-based practice of medicine, personalizing patient …
supporting and contributing to the evidence-based practice of medicine, personalizing patient …
[HTML][HTML] Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer
Stromal content heavily impacts the transcriptional classification of colorectal cancer (CRC),
with clinical and biological implications. Lineage-dependent stromal transcriptional …
with clinical and biological implications. Lineage-dependent stromal transcriptional …
In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins
H Liu, Y Kim, S Sharkis, L Marchionni… - Science translational …, 2011 - science.org
Human induced pluripotent stem cells (iPSCs) are a potential source of hepatocytes for liver
transplantation to treat end-stage liver disease. In vitro differentiation of human iPSCs into …
transplantation to treat end-stage liver disease. In vitro differentiation of human iPSCs into …
[HTML][HTML] Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
…, R Mehra, S Nimmagadda, L Marchionni… - Nature …, 2018 - nature.com
A majority of cancers fail to respond to immunotherapy with antibodies targeting immune
checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)…
checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)…